RxDoctor Payments Data

Manmeet Shergill, MD

Family Medicine · Modesto, CANPI 1184818031

Payments from drug & device makers

$10,972in general payments, 2019–2025

Across 724 payments — averaging $15.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$1K
  • GSK$1K
  • Boehringer Ingelheim$1K
  • Pfizer$781
  • AbbVie$772
  • Amgen$739
  • plus $5K from 45 others

What the payments were for

  • Food & beverage$10,959100%
  • Education$130%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$10,972 in reported general payments places this provider in the 95th percentile of 10,533 family medicine providers in California.

See all family medicine providers in California

Medicare billing

Part B allowed, 2024
$87,963
Medicare patients
206
Services billed
1,350

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Enbrel SureclickEtanercept12$104,096
OzempicSemaglutide64$61,638
JanuviaSitagliptin Phosphate51$51,377
JardianceEmpagliflozin66$45,649
MounjaroTirzepatide40$42,425
EliquisApixaban106$40,518
TrulicityDulaglutide20$23,924
LinzessLinaclotide28$19,265
Trelegy ElliptaFluticasone/Umeclidin/Vilanter24$14,776
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen483$14,043
Breo ElliptaFluticasone/Vilanterol25$11,877
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog24$10,421
BrilintaTicagrelor17$9,446
EntrestoSacubitril/Valsartan11$8,804
Lantus SolostarInsulin Glargine,hum.Rec.Anlog69$8,711

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro, Trulicity$588$66,34960 claims
Novo NordiskOzempic$253$61,63864 claims
MerckJanuvia$187$51,37751 claims
Boehringer IngelheimJardiance$1,027$45,64966 claims
PfizerEliquis$781$40,518106 claims
GSKTrelegy Ellipta, Breo Ellipta, Anoro Ellipta, Incruse Ellipta, Shingrix$1,274$39,67391 claims
AbbVieLinzess$772$19,26528 claims
AstraZenecaBrilinta, Farxiga$1,303$16,57132 claims
NovartisEntresto$163$8,80411 claims
Astellas Pharma US IncMyrbetriq$236$7,54017 claims
Sanofi-aventis U.S. LLCLantus$134$4,59129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,533 family medicine providers in California.

Other family medicine in Modesto

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →